Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy

Diabetes Care

Volumn 32, Issue 2, 2009, Pages 240-244

  Swan, Karena L ^a   Dziura, James D ^a   Steil, Garry M ^b   Voskanyan, Gayane R ^c   Sikes, Kristin A ^a   Steffen, Amy T ^a   Martin, Melody L ^a   Tamborlane, William V ^a   Weinzimer, Stuart A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN, ASP(B28)-;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; INFUSION PUMP; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE; MALE; PHARMACODYNAMICS; STATISTICAL SIGNIFICANCE; CHILD; DRUG EFFECT; EQUIPMENT DESIGN; INSULIN INFUSION; KINETICS; METABOLISM; PATIENT SELECTION;

ADOLESCENT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; KINETICS; MALE; PATIENT SELECTION;

EID: 61849127306     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0595     Document Type: Article

References (11)

1. DCCT Research Group: The effects of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:977-986, 1993
2. The DCCT Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. J Pediatr 125:177-188, 1994
3. DCCT/EDIC Research Group: Prolonged beneficial effects of intensive therapy of diabetes during adolescence: microvascu-lar outcomes four years after conclusion of the Diabetes Control and Complications Trial. Pediatrics 139:804-812, 2001
4. Zinman B, Tildesley H, Chiasson TJ, Tsue E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
5. Howey DC, Bowsher RR, Brunelle RL, WoodworthJR: [Lys(B28), Pro(B29)] human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
6. Mudaliar S, Lindberg FA, Joyce M, Beer-dsen P, Strange P, Lin A, Henry RR: Insulin aspart (B28 Asp-insulin): a fast actinganalog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondia-betic subjects. Diabetes Care 22:1501-1506, 1999
7. Becker RHA, Frick A, Wessels D, Scholtz H: Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine-a novel, rapid-acting, human insulin analogue (Abstract). Diabetologia 46:775, 2003
8. Becker RHA, Frick AD, Kapitza C, Heise T, Rave K: Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine (GLU) versus insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes. Diabetes 53 (Suppl. 2):503, 2004
9. Danne T, Becker RHA, Heise T, Bittner C, Frick AD, Rave K: Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 28: 2100-2105, 2005
10. Swan KL, Weinzimer SA, Steil G, Voskan-yan G, Steffen A, Martin M, Tamborlane WV: Effect of puberty on the pharmaco-dynamic and pharmacokinetic properties of insulin pump therapy in youth with TIDM. Diabetes Care 31:44-46, 2008
11. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979